PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 46690

Title: Biomarkers versus imaging in the early detection of hepatocellular carcinoma, response to treatment and disease progression

Reviewer's code: 00051081

Reviewer's country: Turkey

Science editor: Ruo-Yu Ma

Date sent for review: 2019-02-20

Date reviewed: 2019-02-22

Review time: 2 Hours, 2 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	[ ] Accept (High priority)	Peer-Review:
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] Accept (General priority)	[Y] Anonymous
[Y] Grade C: Good	[Y] Grade C: A great deal of language polishing	[ ] Minor revision	[ ] Onymous
[ ] Grade D: Fair	[ ] Grade D: Rejection	[Y] Major revision	Peer-reviewer's expertise on the topic of the manuscript:
[ ] Grade E: Do not publish		[ ] Rejection	[ ] Advanced
			[Y] General
			[ ] No expertise
			Conflicts-of-Interest:
			[ ] Yes
			[Y] No

SPECIFIC COMMENTS TO AUTHORS

The author has reviewed the recent changes of surrogate markers used for early diagnosis and screening of HCC. Although the findings are interesting the style of manuscript presentation requires a major revision so that a potential reader should read

the message in a systematic manner. The author has written the findings that someone may find it as a PubMed summary of recent studies missing the aim of being a journal article. Therefore, I recommend author to revise the manuscript thoroughly into a newer version which is easy to read and findings presented in a logical-systematic pathway.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

[　] The same title

[　] Duplicate publication

[　] Plagiarism

[Y] No

BPG Search:

[　] The same title

[　] Duplicate publication

[　] Plagiarism

[Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 46690

Title: Biomarkers versus imaging in the early detection of hepatocellular carcinoma, response to treatment and disease progression

Reviewer's code: 03656572

Reviewer's country: China

Science editor: Ruo-Yu Ma

Date sent for review: 2019-02-20

Date reviewed: 2019-02-22

Review time: 7 Hours, 2 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	[ ] Accept (High priority)	Peer-Review:
[Y] Grade B: Very good	[Y] Grade B: Minor language polishing	[Y] Accept (General priority)	[Y] Anonymous
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Minor revision	[ ] Onymous
[ ] Grade D: Fair	[ ] Grade D: Rejection	[ ] Major revision	Peer-reviewer's expertise on the topic of the manuscript:
[ ] Grade E: Do not publish		[ ] Rejection	[Y] Advanced
			[ ] General
			[ ] No expertise
			Conflicts-of-Interest:
			[ ] Yes
			[Y] No

SPECIFIC COMMENTS TO AUTHORS

In this review, the author provided an overview of the current evidence-based information on the clinical utility of serum biomarkers in the early diagnosis of HCC and the prognosis of the disease, including AFP, MicroRNAs, LncRNA and PIVKA-II. The

author concluded that although there are important advances in the role of biomarkers in certain stages of the disease, especially in combinations, large studies are needed on certain population groups to introduce biomarkers into clinical practice on a large scale. It was difficult to find a unique combination of biomarkers in the diagnosis of HCC. Imaging techniques still play a leading role in both surveillance and HCC diagnosis This review is described in detail, which, as valuable information, could help the readers that have better understand the first-hand knowledge of this topic to start novel studies.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

[   ] The same title

[   ] Duplicate publication

[   ] Plagiarism

[Y] No

BPG Search:

[   ] The same title

[   ] Duplicate publication

[   ] Plagiarism

[Y] No